POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)
Launched by UCB PHARMA · Sep 8, 2005
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical history of SAR known and treated since 2 years.
- • Positive skin prick test (wheal \> 3 mm larger than the diluent control) or RAST (≥3.5 IU/ml) to grass pollen (less than 1 year).
- • Minimum mean T5SS of 8 during the baseline period.
- Exclusion Criteria:
- • Have an associated asthma requiring a daily treatment other than β2 short acting agonist prn
- • Have atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids and any other disease requiring the administration of oral or topical corticosteroids
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
UCB Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials